){kind=logo}
Loeb & Loeb represented the managing underwriter, BTIG, in connection with the initial public offering of Translational Development Acquisition Corp., a special purpose acquisition company (SPAC). The SPAC issued 17.25 million units, including 2.25 million units issued through the full exercise of the underwriters’ over-allotment option, at a price of $10.00 per unit. The offering generated gross proceeds of $172.5 million.
The company’s units began trading on December 23, 2024, on the Nasdaq Global Market under the ticker symbol "TDACU." Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols "TDAC" and "TDACW," respectively.
The Loeb team that represented BTIG included Capital Markets partner David Levine and associate Olivia Wang.
For more information, please see Translational Development Acquisition Corp.’s press release.
The company’s units began trading on December 23, 2024, on the Nasdaq Global Market under the ticker symbol "TDACU." Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols "TDAC" and "TDACW," respectively.
The Loeb team that represented BTIG included Capital Markets partner David Levine and associate Olivia Wang.
For more information, please see Translational Development Acquisition Corp.’s press release.
